All Topics
Health Technology Assessment (HTA)
Antimicrobial Resistance (AMR)

Newsletter SignupSubscribe

Search publications, topics, authors and more

All Topics
Health Technology Assessment (HTA)
Antimicrobial Resistance (AMR)

Newsletter SignupSubscribe

Search publications, topics, authors and more

Close

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Real-World Evidence
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme
IRA Programme

Innovation Policy Prize

The Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Prevention
Policy, Organisation and…
Adult Immunisation

The Socio-Economic Value of Adult Immunisation Programmes

Antimicrobial Resistance (AMR)
Policy, Organisation and…
Quality of Life

Capturing the Broader Value of Antibiotics

Health Technology Assessment…
Economics of Innovation
Innovation

Innovation for Health System Efficiency and Improvement

Drug Development/R&D
Value, Affordability, and…
Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

Antimicrobial Resistance (AMR)
Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Health Care Systems
Policy, Organisation and…
Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Health Technology Assessment…
Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Cell and Gene Therapies
Value, Affordability, and…
Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

Close

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Real-World Evidence

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme

IRA Programme
The Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Contact Us

Newsletter SignupSubscribe

External Expert Profile

Antonio Profico

Latest Publications

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Powered by GDPR Cookie Compliance

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

The Socio-Economic Value of Adult Immunisation Programmes

Capturing the Broader Value of Antibiotics

Innovation for Health System Efficiency and Improvement

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Reimagining Prevention for a Healthier, More Prosperous Society

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Are Recommendations for HTA of Gene Therapies Being Achieved?

All Publications

External Expert Profile

Antonio Profico

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)